Andy Hsieh
Stock Analyst at William Blair
(0.76)
# 3,905
Out of 4,959 analysts
12
Total ratings
50%
Success rate
-11.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $9.81 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $3.28 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $3.54 | - | 1 | Feb 28, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Market Perform | n/a | $6.92 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $19.63 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $4.61 | - | 1 | Feb 28, 2025 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $7.74 | - | 1 | Feb 6, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $1.36 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $58.19 | - | 1 | Sep 29, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $11.18 | - | 2 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.75 | - | 1 | Feb 21, 2023 |
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.81
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $3.28
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.54
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $6.92
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $19.63
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.61
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.74
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.36
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $58.19
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.18
Upside: -
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -